Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

Scientists conducted a prospective single-center Phase II trial in which they added autologous anti-CD19 humanized binding domain T cells to ibrutinib in chronic lymphocytic leukemia patients not in complete remission despite at least six months of ibrutinib.